Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
1
25%
Ph not_applicable
2
50%
Ph phase_3
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (25.0%)
Phase 31 (25.0%)
N/A2 (50.0%)

Trials by Status

completed375%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_3

Stop Retinal Ganglion Cell Dysfunction Study

NCT02390284
completedphase_2

Circadian Rhythms of Aqueous Humor Dynamics in Humans

NCT00572936
completednot_applicable

Pupillary Response After Glaucoma Medication

NCT02522039
completednot_applicable

Pharmacological Intervention in Diabetic Retinopathy

NCT00619034

Clinical Trials (4)

Showing 4 of 4 trials
NCT02390284Phase 3

Stop Retinal Ganglion Cell Dysfunction Study

Terminated
NCT00572936Phase 2

Circadian Rhythms of Aqueous Humor Dynamics in Humans

Completed
NCT02522039Not Applicable

Pupillary Response After Glaucoma Medication

Completed
NCT00619034Not Applicable

Pharmacological Intervention in Diabetic Retinopathy

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4